Alissa Cooper, Thoracic Oncologist at Dana-Farber Cancer Institute, shared Stephen Liu’s, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, on X, adding:
“Glad to share this labor of love put together with my colleagues from Memorial Sloan Kettering Cancer Center, Dana-Farber’s Lowe Center for Thoracic Oncology, MGH Thoracic Oncology.
We delve into the granular characteristics and outcomes of 102 pts with de novo SCLC treated with tarlatamab off-trial.”
Quoting Stephen Liu’s post on X:
“Real world outcomes with tarlatamab from Alissa Cooper et al.
In this series, 59% of pts would have been trial eligible. Time on treatment 4.2m for trial-eligible, only 2.1m for trial-ineligible pts. ICANS more common in ineligible group (33% vs 14%).”
Title: Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer
Authors: Alissa J. Cooper, Joyce Liang, Stephanie McDonald, Andrea Arfe, Wiktoria Bogdanska, Jessica S. Rossa, Julia Rivera, Phoebe Clark, Shin Saito, Bobby Daly, Justin F. Gainor, Charles M. Rudin, Jacob Sands, Catherine B. Meador.
Other articles featuring Alissa Cooper and Stephen Liu on OncoDaily.